Triple receptor agonist peptides Retatrutide LY-3437943 benefits in weight

https://www.astersteroids.com/triple-receptor-agon , ist-peptides-retatrutide-
ly-3437943-benefits-i , n-weight-loss/

Purity:98% HPLC
Packing:2mg/vial and 5mg/vial;10vials/box
Min Order: 1box
Payment:Bitcoin,Moneygram and Wester Union
Lead time:24hours after received payment
Safe shipping to US and most of Europe country
Storage:Shading, confined preservation,2-8°C

Retatrutide, number LY-3437943, is arguably the latest promising drug for
weight loss and the treatment of type 2 diabetes in obese/overweight
patients. It has a completely new mode of action, and clinical trials have
shown that it is more effective in weight loss than the FDA-approved
Semagelutide(Wegovy) and Tirzepatide(Mounjaro). Perhaps you have not heard
of this new weight loss peptide, today we will introduce it -Retatrutide.

What is peptides Retatrutide LY-3437943?
For sale Retatrutide LY-3437943 basic information:

Cas No.:2381089-83-2

MF:C223H343F3N46O70

MW: 4845.444

Some approved weight loss products were originally developed to treat type 2
diabetes and work based on things like appetite control and delayed gastric
empting. Retatrutide, a new drug in development for the treatment of
obesity, is a triple receptor agonist that activates the GLP-1(glucagon-like
peptide-1) receptor,GIP(Glucose-dependent insulin stimulating) receptor and
GCGR (glucagon) receptors in the body, an unprecedented way to lose weight.

How does Retatrutide lose weight?
A preliminary understanding of how Retatrutide works for weight loss can be
found in the three receptors it acts on.

GLP-1: Glucagon-like peptide 1
GLP-1 is the key word in the treatment of type 2 diabetes, which mainly
plays a role in regulating blood sugar in the body. it inhibits appetite and
slows stomach emptying, helping to lower blood sugar while also helping with
weight loss, which is why drugs used to treat type 2 diabetes can also be
used for weight loss.

GIP: Glucose-dependent insulin-promoting polypeptide
GIP, also known as gastric inhibitory peptides, reduces hunger and increases
satiety by reducing the secretion of stomach acid and the speed at which
food is transported through the stomach.

Compared with single GLP-1 agonists, GLP-1 and GIP dual agonists increase
overall energy expenditure and reduce caloric intake, thus achieving better
weight loss. This is the mode of action of Tirzepatide, a new type 2
diabetes drug developed by Eli Lilly and Co., which is a double receptor
agonist for GLP-1 and GIP, and is a completely new attempt. Its
effectiveness has been proven and it has been approved by the FDA.
Tirzepatide’s weight loss was equally impressive, showing an average weight
loss of 22.5 percent (about 52 pounds) after 72 weeks of use, while
Semaglutide experienced an average weight loss of about 15 percent (34
pounds) after 68 weeks.

Retatrutide is another Lilly innovation that has a completely new mode of
action, activating GCG(glucagon) receptors in addition to GLP-1 receptors
and GIP receptors.

Minimum Order: 11111 grams

Click to Enlarge